证券日报网讯 1月8日，星宸科技发布公告称，公司拟使用自有资金和/或自筹资金（含股票回购专项贷 款资金等）以集中竞价方式回购部分公司已发行的人民币普通股（A股）股票用于实施股权激励和/或员 工持股计划。本次回购股份的价格为不超过88.90元/股（含），回购价格上限未超过公司董事会审议通 过回购股份方案前30个交易日公司股票交易均价的150%，拟回购资金总额不低于人民币6，000万元 （含），不超过人民币12，000万元（含）。回购期限为自公司董事会审议通过本次回购方案之日起不 超过12个月。 （文章来源：证券日报） ...

智通财经APP讯，星宸科技(301536.SZ)公告，公司拟使用自有资金和/或自筹资金(含股票回购专项贷款 资金等)以集中竞价方式回购部分公司已发行的普通股(A股)股票用于实施股权激励和/或员工持股计划。 本次回购股份的价格为不超过88.90元/股(含)，拟回购资金总额不低于6000万元(含)，不超过1.2亿元 (含)。回购期限为自公司董事会审议通过本次回购方案之日起不超过12个月。 ...

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) has received a loan commitment letter from China Merchants Bank Yantai Branch to support its share repurchase financing, with specific terms outlined [1] Group 1: Loan Details - The loan amount is capped at RMB 170 million, which cannot exceed 90% of the actual repurchase amount [1] - The loan term is set for a maximum of 36 months [1] - The validity period of the commitment letter is from the date of issuance until January 5, 2027 [1]

Core Viewpoint - The company, Stone Four Pharmaceutical Group, has been actively repurchasing its shares, indicating a potential confidence in its stock value and future performance [2] Summary by Category Share Buyback Activity - On January 8, the company repurchased 1.486 million shares at a price range of HKD 3.030 to HKD 3.050, totaling HKD 4.5217 million [2] - The stock closed at HKD 3.050 on the same day, reflecting a 0.99% increase, with a total trading volume of HKD 20.5504 million [2] - Since January 5, the company has conducted share buybacks for four consecutive days, accumulating a total of 5.214 million shares repurchased, with a total expenditure of HKD 15.585 million [2] - During this period, the stock price has increased by 6.64% [2] Buyback Details - The detailed buyback information is as follows: - January 8: 1.486 million shares at a maximum price of HKD 3.050 and a minimum price of HKD 3.030, totaling HKD 4.5217 million [2] - January 7: 1.128 million shares at a maximum price of HKD 3.030 and a minimum price of HKD 3.010, totaling HKD 3.4063 million [2] - January 6: 1.500 million shares at a maximum price of HKD 3.000 and a minimum price of HKD 2.960, totaling HKD 4.4694 million [2] - January 5: 1.100 million shares at a maximum price of HKD 2.920 and a minimum price of HKD 2.890, totaling HKD 3.1876 million [2]

东诚药业公告称，2025年12月31日公司通过以集中竞价方式回购股份方案，回购价不超18元/股，资金1 亿 - 2亿元，期限不超12个月。近日，公司获招商银行烟台分行《贷款承诺函》，贷款不超1.7亿元（不 超实际回购金额90%），期限不超36个月，承诺函至2027年1月5日有效。本次贷款不构成关联交易，不 影响公司经营及业绩，公司将依规实施回购并披露信息。 ...

Core Insights - AZZ Inc. reported strong financial performance for the third quarter of fiscal year 2026, with an EPS of $1.52, exceeding analysts' expectations of $1.43 [1][6] - The company's revenue reached approximately $425.7 million, a 5.5% increase year-over-year, driven primarily by a 15.7% surge in Metal Coatings sales [2][6] - Net income for the quarter was $41.1 million, reflecting a 22.2% increase from the previous year [3][6] Financial Performance - Revenue for the third quarter was approximately $425.7 million, surpassing forecasts of $418.2 million [2] - Metal Coatings sales increased by 15.7% to $195 million, while Precoat Metals sales slightly declined by 1.8% to $230.7 million [2] - Adjusted net income rose by 9.7% to $46 million, with GAAP diluted EPS increasing by 21.4% to $1.36 [3] Shareholder Returns and Debt Management - The company repurchased 201,416 shares for $20 million at an average price of $99.28 per share [4] - AZZ reduced its debt by $35 million during the quarter, contributing to a year-to-date debt reduction of $325.4 million [4] - Cash provided by operating activities increased by 20% to $79.7 million, and a cash dividend of $0.20 per share was paid to common shareholders [4] Valuation Metrics - The company has a price-to-earnings (P/E) ratio of approximately 10.23, indicating a positive market valuation of its earnings [5] - The price-to-sales ratio stands at about 2.04, and the enterprise value to sales ratio is around 2.06 [5] - AZZ's debt-to-equity ratio is 0.024, and the current ratio is approximately 1.66, demonstrating a solid ability to cover short-term liabilities [5]

每经AI快讯，Wind数据显示，1月7日，共42只港股获公司回购，6只个股回购金额超千万港元。其中， 腾讯控股、小米集团-W、吉利汽车回购金额最大，分别获公司回购6.36亿港元、1.49亿港元、5915.6万 港元。截至1月7日，今年已有70只港股获公司回购，3只个股年内累计回购金额超亿港元。其中，腾讯 控股、小米集团-W、吉利汽车年内累计回购金额最大，分别获公司回购25.43亿港元、4.48亿港元、 1.27亿港元。 （文章来源：每日经济新闻） ...

Core Viewpoint - On January 8, a total of 8 companies announced progress related to stock buybacks, with 5 companies disclosing ongoing buyback implementations and 3 companies completing their buyback plans [1] Group 1: Buyback Implementation Progress - The companies with the highest buyback amounts are Jian Sheng Group, Dongcheng Pharmaceutical, and Minsheng Health, with buybacks of 118 million, 17.1863 million, and 14.9993 million respectively [1] - As of January 8, 29 buyback plans have been completed this year, involving 22 companies, with 7 companies having completed buybacks exceeding 100 million [1] Group 2: Completed Buybacks - The companies that completed buybacks exceeding 10 million on that day are Jingxin Pharmaceutical, Huachangda, and Shibu Detection, with completed buybacks of 609 million, 41.8996 million, and 31.9512 million respectively [1] - The leading companies in terms of completed buyback amounts are BOE Technology Group, Jingxin Pharmaceutical, and New Hualian, with completed buybacks of 1.5 billion, 609 million, and 556 million respectively [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 一、股份回购方案基本情况 四川百利天恒药业股份有限公司（以下简称"公司"）于2025年12月30日召开了第五届董事会第五次会 议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金和/或 自筹资金以集中竞价交易方式回购公司已发行的部分人民币普通股（A股）股票，拟回购资金总额不低 于人民币10,000万元（含），不超过人民币20,000万元（含），回购的股份将在未来适宜时机全部用于 实施员工持股计划或股权激励。本次回购价格不超过人民币546元/股（含），回购股份期限为自公司董 事会审议通过股份回购方案之日起12个月内。 具体内容详见公司于2025年12月31日刊登于上海证券交易所网站（www.sse.com.cn）的《四川百利天恒 药业股份有限公司关于以集中竞价交易方式回购股份的预案》（公告编号：2025-093）。 二、取得金融机构股票回购专项贷款承诺函的具体情况 近日，公司取得中国银行股份有限公司四川省分行出具的《贷款承诺函》，主要内容如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688506 证券简称：百利天恒 公告编号：2026-002 四川百利天恒药业股份有限公司 关于取得金融机构股票回购专项贷款承诺函的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、股份回购方案基本情况 四川百利天恒药业股份有限公司（以下简称"公司"）于2025年12月30日召开了第五届董事会第五次会 议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金和/或 自筹资金以集中竞价交易方式回购公司已发行的部分人民币普通股（A股）股票，拟回购资金总额不低 于人民币10,000万元（含），不超过人民币20,000万元（含），回购的股份将在未来适宜时机全部用于 实施员工持股计划或股权激励。本次回购价格不超过人民币546元/股（含），回购股份期限为自公司董 事会审议通过股份回购方案之日起12个月内。 具体内容详见公司于2025年12月31日刊登于上海证券交易所网站（www.sse.com.cn）的《四川百利天恒 药业股份有限公司关于以 ...